Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
作者： R L Burkes , R J Ginsberg , F A Shepherd , M E Blackstein , M E Goldberg
DOI: 10.1200/JCO.1992.10.4.580
关键词:
摘要: PURPOSEThe 5-year survival rates with surgical resection for preoperatively identified stage IIIA N2 non-small-cell lung cancer (NSCLC) are less than 10%. A pilot study of mitomycin, vindesine, and cisplatin (MVP) induction chemotherapy was undertaken in an attempt to improve the curative potential surgery this group patients.PATIENTS AND METHODSThirty-nine patients mediastinoscopy NSCLC received two cycles MVP. Responding underwent thoracotomy further courses MVP.RESULTSThe overall response rate 64% (25 39) three complete 22 partial responses. Twenty-two were resected, which included a radical mediastinal node dissection. Eighteen resections four incomplete. Pathologically, (7.7%) had no tumor remaining. Toxicity postoperative deaths secondary bronchopleural (BP) fistula, mitomycin pulmonary toxicity patients, septic patients. Twenty-e...
sci-hub.se 参考文章(13)
F.G. Pearson, N.C. DeLarue, R. lives, T.R.J. Todd, J.D. Cooper, Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 83, pp. 1- 11 ,(1982) , 10.1016/S0022-5223(19)37318-0
Twohig Kj, Matthay Ra, Pulmonary effects of cytotoxic agents other than bleomycin. Clinics in Chest Medicine. ,vol. 11, pp. 31- 54 ,(1990)
Nael Martini, Betty J. Flehinger, The role of surgery in N2 lung cancer. Surgical Clinics of North America. ,vol. 67, pp. 1037- 1049 ,(1987) , 10.1016/S0039-6109(16)44341-0
Clifton F. Mountain, A new international staging system for lung cancer Chest. ,vol. 89, pp. 225- 233 ,(1986) , 10.1378/CHEST.89.4_SUPPLEMENT.225S
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Jaap Verweij, Thea van Zanten, Tjeu Souren, Richard Golding, Herbert M. Pinedo, Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer. ,vol. 60, pp. 756- 761 ,(1987) , 10.1002/1097-0142(19870815)60:4<756::AID-CNCR2820600408>3.0.CO;2-H
Arthur Skarin, Maxine Jochelson, Thomas Sheldon, Arnold Malcolm, Peter Oliynyk, Richard Overholt, Myla Hunt, Emil Frei, Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: Long-term follow-up in 41 patients Journal of Surgical Oncology. ,vol. 40, pp. 266- 274 ,(1989) , 10.1002/JSO.2930400413
Frederick O. Stephens, The case for a name change from neoadjuvant chemotherapy to induction chemotherapy. Cancer. ,vol. 63, pp. 1245- 1246 ,(1989) , 10.1002/1097-0142(19890401)63:7<1245::AID-CNCR2820630702>3.0.CO;2-C
RICHARD J. GRALLA, Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules Annals of Internal Medicine. ,vol. 95, pp. 414- 420 ,(1981) , 10.7326/0003-4819-95-4-414
Dan Luedke, Timothy T. McLaughlin, Carlos Daughaday, Susan Luedke, Bruce Harrison, Garry Reed, Orlando Martello, Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression Cancer. ,vol. 55, pp. 542- 545 ,(1985) , 10.1002/1097-0142(19850201)55:3<542::AID-CNCR2820550312>3.0.CO;2-9